Main Area of Focus

Allow the research community access to clinical data sets to harness the power of data to generate new knowledge to understand, treat, and prevent infectious diseases such as COVID-19.

Main Areas of Focus

Research projects will include surveillance studies to identify previously unknown viral causes of febrile illnesses in humans, the animal sources of viral or other disease-causing pathogens, and to determine what genetic or other changes make these pathogens capable of infecting humans. Other research by the CREID investigators will involve developing reagents and diagnostic assays to improve detection of emerging pathogens as well as studies aimed at detailing human immune responses to new or emerging infectious agents. Overall, the breadth of research projects to be carried out in the CREID network will allow for study of disease spillover in multiple phases of the process: where pathogens first emerge from an animal host; at the borders between wild and more populated areas, where and when rapid human-to-human transmission occurs; and, finally, how transmission is facilitated in urban areas, where epidemic spread can occur.

Locations

Primary awardees for the CREID network and regions of focus include: 

• Donald Brambilla, Ph.D., RTI International, Research Triangle Park, North Carolina
• Tony Moody, M.D., Duke University School of Medicine, Durham, North Carolina
  CREID Coordinating Center
• Kristian Andersen, Ph.D., Scripps Research, La Jolla, California
  West African Emerging Infectious Disease Research Center
  West Africa
• Eva Harris, Ph.D., University of California, Berkeley
  American and Asian Centers for Arboviral Research and Enhanced Surveillance (A2CARES)
  Central and South America, South Asia
• Christine Johnson, VMD, Ph.D., University of California, Davis, School of Veterinary Medicine
  Epicenter for Emerging Infectious Disease Intelligence
  Central Africa and South America
• M. Kariuki Njenga, Ph.D., Washington State University, Pullman
  Center for Research in Emerging Infectious Diseases-East and Central Africa
  East and Central Africa
• Anavaj Sakuntabhai, Ph.D., Institut Pasteur, Paris, France 
  West Africa and Southeast Asia
• Nikos Vasilakis, Ph.D., University of Texas Medical Branch, Galveston
  Central and South America
• Wesley C. Van Voorhis, M.D., Ph.D., University of Washington, Seattle
  South America, West and South Africa, Middle East, and Asia
• David Wang, Ph.D., Washington University School of Medicine, St. Louis, Missouri 
  Asia, East Africa
• Scott C. Weaver, Ph.D., University of Texas Medical Branch, Galveston
  West Africa

Main Areas of Focus

TATFAR’s goal is to improve cooperation between the United States and EU in three key areas:

1. Appropriate therapeutic use of antimicrobial drugs in medical and veterinary communities
2. Prevention of healthcare- and community-associated drug-resistant infections
3. Strategies for improving the pipeline of new antimicrobial drugs

Major Areas of Focus

CARB-X is focused on the preclinical discovery and development and Phase 1 clinical trials of new antibacterial products (including therapeutics, vaccines, and diagnostics) to help address the threat of antibiotic resistance.

Over the last several decades there has been a continual withdrawal of pharmaceutical companies engaged in developing new antibiotics. In 1990, there were at least 18 large pharmaceutical companies actively developing antibiotics. As of April 2020, there are 4. 

CARB-X provides funding for companies with innovative and promising solutions to antibiotic resistance. CARB-X also provides the business support and drug development expertise to that companies, including start-ups, need to increase their odds of success. NIAID provides technical support and preclinical drug development services to CARB-X awardees.